CanSino Biologics Inc.

6185

CNE100003F01

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:09 2025-06-19 am EDT			5-day change	1st Jan Change
33.50 ^HKD	-3.74%		-6.69%	+6.35%

May. 15	CanSino Biologics Gets Clinical Trial Approval for TB Vaccine from Indonesian Regulator	MT
May. 15	Cansino Biologics Says Inhaled TB Booster Obtains Clinical Trial Approval In Indonesia	RE

CanSino Biologics Narrows Loss in Q1

Published on 04/30/2025 at 09:08

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about CanSino Biologics Inc.

CanSino Biologics Gets Clinical Trial Approval for TB Vaccine from Indonesian Regulator	May. 15	MT
Cansino Biologics Says Inhaled TB Booster Obtains Clinical Trial Approval In Indonesia	May. 15	RE
Cansino Biologics Inc. Obtains Phase I Clinical Trial Approval Granted by the Badan Pengawas Obat Dan Makanan, Republik Indonesia	May. 15	CI
CanSino Biologics Narrows Loss in Q1	Apr. 30	MT
Cansino Biologics Posts QTRLY Operating Revenue Of RMB137.2 Million	Apr. 29	RE
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 29	CI
Tadawul Shares Soar as Saudi Arabia Plans to Invest in Gold, Phosphate Projects	Mar. 26	MT
CanSino Biologics Loss Shrinks in 2024	Mar. 26	MT
Spimaco Secures Exclusive Right to Produce, Commercialize CanSino's Meningococcal Vaccine in Saudi Arabia, Other Markets	Mar. 26	MT
Saudi Pharmaceutical Industries and Medical Appliances Corporation and CanSino Biologics Inc. Signs Collaboration Agreement for the Supply, Manufacturing, and Commercialization of MCV4 Vaccine in Saudi Arabia and Selected MENA Markets	Mar. 25	CI
CanSino Biologics Inc. announced that it expects to receive CNY 300 million in funding	Mar. 24	CI
CanSino Biologics' 2024 Loss Narrows as Revenue Surges 137%	Feb. 27	MT
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 27	CI
CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine	Feb. 24	MT
CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China	Feb. 24	RE
CanSino Biologics Inc. Receives Approval For Clinical Trial Of DTcP-Hib-MCV4 Combined Vaccine	Feb. 24	CI
CanSino Biologics Combined Vaccine for Infants Gets Priority Review Status from Chinese Regulator	Feb. 07	MT
Cansino Biologics Says NMPA Grants Priority Review Status To NDA For DTcP Infant	Feb. 07	RE
CanSino Biologics Inc. Announces Center for Drug Evaluation, NMPA Granted Priority Review Status to NDA for DTCP Infant	Feb. 07	CI
Chinese Regulator Accepts CanSino Biologics' New Drug Application for Tetanus Vaccine	Feb. 06	MT
National Medical Products Administration of the People's Republic of China Grants Notice of Acceptance to CanSino Biologics Inc.'S New Drug Application for the Contained Tetanus Vaccine	Feb. 06	CI
CanSino Biologics Expects Narrower Attributable Loss in 2024	Jan. 17	MT
CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2024 to December 31, 2024	Jan. 17	CI
CanSino Biologics Inc. Announces Menhycia Obtains Drug Registration Certificate in Indonesia	Dec. 30	CI
CanSino Biologics Begins Trial for Tetanus, Diptheria, Acellular Pertussis Shots	Dec. 23	MT

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Employees

1,105

Sector

Pharmaceuticals

Calendar

Aug. 21 - Q2 2025 Earnings Release (Projected)

More about the company